Please find our RSM India Newsflash on the Analysis of the Budget 2026 for the Pharma and Life Science Industry, which highlights the key policy announcements and tax proposals relevant to the sector.

The Newsflash provides an overview of the Government’s continued focus on strengthening healthcare infrastructure, promoting biopharma manufacturing and research, expanding medical education and allied health capabilities, and advancing medical value tourism.

It also outlines the major direct and indirect tax proposals under the Finance Bill, 2026, including changes impacting buy-back taxation, MAT, transfer pricing, procedural compliances, GST, customs duty rationalization and other sector-specific measures.

We trust this analysis will assist you in understanding the key Budget proposals and their implications for the Pharma and Life Science Industry.

Click Here to Download- RSM India Newsflash - Analysis of the Budget 2026 for the Pharma and Life Science Industry